LDE225 versus temozolomide in patients with medulloblastoma

• Research type

  Research Study

• Full title

  A Phase III multicentre open label randomised controlled study of the efficacy and safety of oral LDE225 versus temozolomide in patients with hedgehog pathway activated relapsed medulloblastoma

• IRAS ID

  117407

• Contact name

  Darren Hargrave

• Contact email

  darren.hargrave@nhs.net

• Sponsor organisation

  Novartis Pharma Services

• Eudract number

  2012-003066-40

• Clinicaltrials.gov Identifier

  NCT01708174

• REC name

  London - Hampstead Research Ethics Committee

• REC reference

  13/LO/0120

• Date of REC Opinion

  22 Apr 2013

• REC opinion

  Further Information Favourable Opinion